Drug Guidance for Subsidy 04/06/2025 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teripa... See all × 04/06/2025 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Evenity Injection, Solution 105 mg/1.17 mL Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital National University Hospital Sengkang General Hospital Singapore General Hospital
SUBCUTANEOUS Select a brand starting with the letter: E EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML [SIN16208P]